\n\n\n \n \n\n \n \n \n \n\n\n \n\n \n\n Sep 29, 2009 8:30 AM EDT
\n\n \n Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo - Marketwire\n \n \n | \n\n \n\n \n\n \n\n Sep 22, 2009 9:03 AM EDT
\n\n \n Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance - Marketwire\n \n \n | \n\n \n\n \n\n \n\n Aug 05, 2009 8:05 AM EDT
\n\n \n Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited - Marketwire\n \n \n | \n\n \n\n \n\n \n\n Jul 30, 2009 8:00 AM EDT
\n\n \n Novogen Director Retires - Marketwire\n \n \n | \n\n \n\n \n\n \n\n Jul 08, 2009 11:36 AM EDT
\n\n \n Integrity Media Identifies Market Actives: IFSL, GRVY, NVGN, AMGN, THC, DCP, FDO - PR Newswire\n \n \n | \n\n \n\n \n\n \n\n Jul 07, 2009 8:00 AM EDT
\n\n \n Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells - Marketwire\n \n \n | \n\n \n\n \n\n \n\n Jun 17, 2009 8:30 AM EDT
\n\n \n Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial - Marketwire\n \n \n | \n\n \n\n \n | \n
\n\n
\n\n");